Targeting the genetic alterations of the PI3K–AKT–mTOR pathway: Its potential use in the treatment of bladder cancers

N Houédé, P Pourquier - Pharmacology & therapeutics, 2015 - Elsevier
Urothelial carcinoma of the bladder is the most frequent tumor of the urinary tract and
represents the fifth cause of death by cancer worldwide. The current first line chemotherapy …

[HTML][HTML] Persistent androgen receptor addiction in castration-resistant prostate cancer

MT Schweizer, EY Yu - Journal of hematology & oncology, 2015 - Springer
It is now understood that persistent activation of the androgen receptor (AR) signaling
pathway often underlies the development of castration-resistant prostate cancer (CRPC) …

[HTML][HTML] Prostate cancer and the unfolded protein response

M Storm, X Sheng, YJ Arnoldussen, F Saatcioglu - Oncotarget, 2016 - ncbi.nlm.nih.gov
The endoplasmic reticulum (ER) is an essential organelle that contributes to several key
cellular functions, including lipogenesis, gluconeogenesis, calcium storage, and organelle …

Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer

M Kato, CA Banuelos, Y Imamura, JK Leung… - Clinical Cancer …, 2016 - AACR
Abstract Purpose: The PI3K/Akt/mTOR pathway is activated in most castration-resistant
prostate cancers (CRPC). Transcriptionally active androgen receptor (AR) plays a role in the …

Long non‐coding RNA PRRT3‐AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy

L Fan, H Li, W Wang - Experimental physiology, 2020 - Wiley Online Library
New Findings What is the central question of this study? What is the role of lncRNA PRRT3‐
AS1 in the regulation of peroxisome proliferator‐activated receptor γ (PPARγ) gene …

[HTML][HTML] The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence

D Schörghofer, K Kinslechner, A Preitschopf… - Reproductive Biology …, 2015 - Springer
Background Human prostate cancer represents one of the most frequently diagnosed
cancers in men worldwide. Currently, diagnostic methods are insufficient to identify patients …

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action

C Hu, H Xia, S Bai, J Zhao, H Edwards… - Journal of cellular …, 2020 - Wiley Online Library
Targeting the androgen receptor (AR) signalling pathway remains the main therapeutic
option for advanced prostate cancer. However, resistance to AR‐targeting inhibitors …

[HTML][HTML] Molecular landscape of prostate cancer: implications for current clinical trials

G Khemlina, S Ikeda, R Kurzrock - Cancer treatment reviews, 2015 - Elsevier
Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with
androgen-deprivation therapy has plateaued. Next-generation sequencing studies have led …

[HTML][HTML] MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis

D Barros-Silva, P Costa-Pinheiro, H Duarte… - Cell death & …, 2018 - nature.com
Upregulation of MYC and miRNAs deregulation are common in prostate cancer (PCa).
Overactive MYC may cause miRNAs' expression deregulation through transcriptional and …

[HTML][HTML] Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer

S Perner, MV Cronauer, AJ Schrader, H Klocker… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract Prostate Cancer (PCa) is an important age-related disease being the most common
cancer malignancy and the second leading cause of cancer mortality in men in Western …